Statistics for Xilio Therapeutics, (id:8370 XLO)
Valuation metrics
Market cap
43.85M
Enterprise value
-9,561,287.00
Trailing P/E (ttm)
-0.32
Forward P/E
-1.72
PEG ratio
-1.72
Price/Sales (ttm)
18.61
Price/Book (mrq)
0.75
Enterprise Value/Revenue
-4.06
Enterprise Value/EBITDA
0.15
Overview
Shares outstanding
43.95M
Float
22.62M
Shares short
104.75K
% Held by insiders
0.41%
% Held by institutions
0.30%
Average volume (10 days)
399.35K
Average volume (90 days)
Price summary
52-Week low
0.49
52-Week high
1.93
52-Week change
-24.44%
Beta
-0.20
50-Day moving average
0.89
200-Day moving average
0.92
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
June 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
-622.57%
Operational effectiveness
Return on assets
-45.76%
Return on equity
-130.03%
Income statement
Revenue (ttm)
0.05
Revenue per share (ttm)
0.05
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
-64,907,000.00
Net income to common (ttm)
-65,531,000.00
Diluted EPS (ttm)
-1.98
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
74.95M
Total cash per share (mrq)
1.70
Total debt (mrq)
8.69M
Total Debt/Equity (mrq)
26.00
Current ratio (mrq)
201.90%
Book value per share (mrq)
1.33
Cash flow
Cash flow statement
-17,345,000.00
Levered free cash flow (LFCF)
-3,613,000.00